Not logged in
Talk
Contributions
Create account
Log in
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Page
Discussion
Edit
Edit source
View history
Editing
Trials (Turku University Hospital Cancer Centre)
(section)
From Beacon
Jump to:
navigation
,
search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Trials: How to participate === '''Contact information:''' [https://www.tyks.fi/en/about-tyks/tyks-organization/result-groups/result-group-gynaecology-and-paediatrics/pediatric-clinical-trials-unit-pedctu-turku Click here to access]. '''NCTID''': NCT03486873 '''Title''': [[hasTrialTitle::Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)]] '''Study Summary''': The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2018-08-21 '''Last Updated''': 2023-11-27 '''Number of Patients''': 2300 '''Recruitment Status''': RECRUITING '''Condition''': Solid Tumors '''NCTID''': NCT04607421 '''Title''': [[hasTrialTitle::A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer]] '''Study Summary''': The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnormal gene called "BRAF"; and * has not received prior treatment. Participants in this study will receive one of the following study treatments: * Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. * Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home. * Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home. The study team will monitor how each participant responds to the study treatment for up to about 3 years. '''Sponsor''': Pfizer '''Intervention''': Encorafenib '''Start Date''': 2020-12-21 '''Last Updated''': 2023-09-11 '''Number of Patients''': 815 '''Recruitment Status''': RECRUITING '''Condition''': Neoplasms '''NCTID''': NCT01964430 '''Title''': [[hasTrialTitle::Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)]] '''Study Summary''': The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone. '''Sponsor''': Celgene '''Intervention''': nab-Paclitaxel '''Start Date''': 2014-03-28 '''Last Updated''': 2023-06-28 '''Number of Patients''': 866 '''Recruitment Status''': COMPLETED '''Condition''': Pancreatic Neoplasms '''NCTID''': NCT02450331 '''Title''': [[hasTrialTitle::A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection]] '''Study Summary''': This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab '''Start Date''': 2015-10-05 '''Last Updated''': 2023-06-18 '''Number of Patients''': 809 '''Recruitment Status''': TERMINATED '''Condition''': Carcinoma, Transitional Cell '''NCTID''': NCT04114825 '''Title''': [[hasTrialTitle::Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer]] '''Study Summary''': This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V). '''Sponsor''': RhoVac APS '''Intervention''': RV001V '''Start Date''': 2019-11-19 '''Last Updated''': 2021-09-28 '''Number of Patients''': 180 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Prostate Cancer Recurrent '''NCTID''': NCT00003304 '''Title''': [[hasTrialTitle::Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors]] '''Study Summary''': RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients with recurrent oligodendroglial tumors following combination chemotherapy. '''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC '''Intervention''': temozolomide '''Start Date''': 1998-04 '''Last Updated''': 2012-03-06 '''Number of Patients''': 29 '''Recruitment Status''': COMPLETED '''Condition''': Brain and Central Nervous System Tumors '''NCTID''': NCT04680052 '''Title''': [[hasTrialTitle::A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma]]. '''Study Summary''': This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL. '''Sponsor''': Incyte Corporation '''Intervention''': tafasitamab '''Start Date''': 2021-04-15 '''Last Updated''': 2023-08-18 '''Number of Patients''': 654 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Follicular Lymphoma '''NCTID''': NCT04923893 '''Title''': [[hasTrialTitle::A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy]] '''Study Summary''': The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS). '''Sponsor''': Janssen Research & Development, LLC '''Intervention''': Bortezomib '''Start Date''': 2021-08-19 '''Last Updated''': 2023-11-09 '''Number of Patients''': 650 '''Recruitment Status''': RECRUITING '''Condition''': Multiple Myeloma '''NCTID''': NCT00003805 '''Title''': [[hasTrialTitle::Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count]] '''Study Summary''': RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease. '''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC '''Intervention''': piperacillin sodium '''Start Date''': 1997-11 '''Last Updated''': 2012-09-24 '''Number of Patients''': 859 '''Recruitment Status''': COMPLETED '''Condition''': Bone Marrow Suppression '''NCTID''': NCT00002763 '''Title''': [[hasTrialTitle::High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma]] '''Study Summary''': RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of high- or low-dose interferon alfa with that of no further therapy following surgery in treating patients who have stage III melanoma. '''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC '''Intervention''': recombinant interferon alfa '''Start Date''': 1996-04 '''Last Updated''': 2011-11-16 '''Number of Patients''': 1000 '''Recruitment Status''': UNKNOWN '''Condition''': Melanoma (Skin) '''NCTID''': NCT00255606 '''Title''': [[hasTrialTitle::Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer]] '''Study Summary''': RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of docetaxel and prednisone is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying two different schedules of docetaxel and prednisone to compare how well they work in treating patients with metastatic prostate cancer. '''Sponsor''': Tampere University '''Intervention''': docetaxel '''Start Date''': 2005-08 '''Last Updated''': 2013-06-26 '''Number of Patients''': 360 '''Recruitment Status''': COMPLETED '''Condition''': Prostate Cancer '''NCTID''': NCT02343406 '''Title''': [[hasTrialTitle::Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas]] '''Study Summary''': This study was conducted to evaluate the efficacy and safety of depatuxizumab mafodotin (ABT-414) alone or with temozolomide versus temozolomide or lomustine alone in adult participants with recurrent glioblastoma. The study also included a substudy to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population. '''Sponsor''': AbbVie '''Intervention''': Depatuxizumab mafodotin '''Start Date''': 2015-02-17 '''Last Updated''': 2020-05-22 '''Number of Patients''': 266 '''Recruitment Status''': COMPLETED '''Condition''': Glioblastoma '''NCTID''': NCT00003991 '''Title''': [[hasTrialTitle::Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia]] '''Study Summary''': RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission. PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy. '''Sponsor''': Maxim Pharmaceuticals '''Intervention''': aldesleukin '''Start Date''': 1998-07 '''Last Updated''': 2013-11-06 '''Number of Patients''': 360 '''Recruitment Status''': COMPLETED '''Condition''': Leukemia '''NCTID''': NCT05429268 '''Title''': [[hasTrialTitle::Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)]] '''Study Summary''': The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). '''Sponsor''': Incyte Corporation '''Intervention''': Tafasitamab '''Start Date''': 2022-12-23 '''Last Updated''': 2023-11-24 '''Number of Patients''': 81 '''Recruitment Status''': RECRUITING '''Condition''': Large B-Cell Lymphoma '''NCTID''': NCT03155997 '''Title''': [[hasTrialTitle::Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer]] '''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. '''Sponsor''': Eli Lilly and Company '''Intervention''': Abemaciclib '''Start Date''': 2017-07-12 '''Last Updated''': 2023-07-14 '''Number of Patients''': 5637 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Breast Cancer '''NCTID''': NCT03395197 '''Title''': [[hasTrialTitle::Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC]] '''Study Summary''': This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide. '''Sponsor''': Pfizer '''Intervention''': Talazoparib with enzalutamide '''Start Date''': 2017-12-18 '''Last Updated''': 2023-08-02 '''Number of Patients''': 1125 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': mCRPC '''NCTID''': NCT04821622 '''Title''': [[hasTrialTitle::Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC]] '''Study Summary''': The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC. '''Sponsor''': Pfizer '''Intervention''': talazoparib plus enzalutamide '''Start Date''': 2021-05-12 '''Last Updated''': 2023-11-22 '''Number of Patients''': 599 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Prostate Cancer '''NCTID''': NCT03745222 '''Title''': [[hasTrialTitle::A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer]] '''Study Summary''': This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy versus cCRT alone, and tislelizumab given sequentially after cCRT versus cCRT alone, in newly diagnosed stage III subjects with locally advanced, unresectable non-small cell lung cancer (NSCLC). The primary endpoint is centrally-assessed progression free survival (PFS) in the intent-to-treat (ITT) population. . '''Sponsor''': Celgene '''Intervention''': Tislelizumab '''Start Date''': 2019-05-22 '''Last Updated''': 2020-07-15 '''Number of Patients''': 1 '''Recruitment Status''': TERMINATED '''Condition''': Carcinoma, Non-Small-Cell Lung '''NCTID''': NCT04557059 '''Title''': [[hasTrialTitle::A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer]] '''Study Summary''': The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone. '''Sponsor''': Janssen Pharmaceutica N.V., Belgium '''Intervention''': Radiotherapy '''Start Date''': 2020-11-12 '''Last Updated''': 2023-11-09 '''Number of Patients''': 412 '''Recruitment Status''': RECRUITING '''Condition''': Prostatic Neoplasms '''NCTID''': NCT05317416 '''Title''': [[hasTrialTitle::Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant]] '''Study Summary''': The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years '''Sponsor''': Pfizer '''Intervention''': Elranatamab '''Start Date''': 2022-03-25 '''Last Updated''': 2023-11-03 '''Number of Patients''': 760 '''Recruitment Status''': RECRUITING '''Condition''': Multiple Myeloma '''NCTID''': NCT04392505 '''Title''': [[hasTrialTitle::Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study]] '''Study Summary''': The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying biological characteristics. '''Sponsor''': Oslo University Hospital '''Intervention''': Durvalumab Injection '''Start Date''': 2020-05-11 '''Last Updated''': 2022-10-25 '''Number of Patients''': 100 '''Recruitment Status''': RECRUITING '''Condition''': Cancer '''NCTID''': NCT00342316 '''Title''': [[hasTrialTitle::Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia]] '''Study Summary''': This study compares overall survival between patients with acute myeloid leukemia, who are in complete remission following initial treatment with chemotherapy and whose remission is maintained either with a transplantation of stem cells obtained from a sibling or unrelated donor or with standard treatment, which is additional chemotherapy. The study hypothesis is that the group transplanted with stem cells from a donor will have a superior survival compared with patients treated with standard of care. '''Sponsor''': Vastra Gotaland Region '''Intervention''': Reduced Intensity Conditioning Stem Cell Transplantation '''Start Date''': 2003-12-18 '''Last Updated''': 2020-01-27 '''Number of Patients''': 340 '''Recruitment Status''': COMPLETED '''Condition''': Acute Myeloid Leukemia '''NCTID''': NCT05159245 '''Title''': [[hasTrialTitle::The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs]] '''Study Summary''': This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test. '''Sponsor''': Helsinki University Central Hospital '''Intervention''': Alectinib '''Start Date''': 2021-12-10 '''Last Updated''': 2023-09-22 '''Number of Patients''': 250 '''Recruitment Status''': RECRUITING '''Condition''': Advanced Cancer '''NCTID''': NCT04725188 '''Title''': [[hasTrialTitle::Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)]] '''Study Summary''': The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab/Vibostolimab coformuation '''Start Date''': 2021-04-20 '''Last Updated''': 2023-07-06 '''Number of Patients''': 255 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Metastatic Non Small Cell Lung Cancer '''NCTID''': NCT05116189 '''Title''': [[hasTrialTitle::Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)]] '''Study Summary''': The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\] ≥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for all participants. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2021-12-13 '''Last Updated''': 2023-08-08 '''Number of Patients''': 616 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Ovarian Cancer '''NCTID''': NCT04003610 '''Title''': [[hasTrialTitle::Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)]] '''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received prior treatment. '''Sponsor''': Incyte Corporation '''Intervention''': Pemigatinib '''Start Date''': 2020-05-14 '''Last Updated''': 2022-05-26 '''Number of Patients''': 7 '''Recruitment Status''': TERMINATED '''Condition''': Metastatic Urothelial Carcinoma '''NCTID''': NCT02302807 '''Title''': [[hasTrialTitle::A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]]] '''Study Summary''': This is a Phase III, global, multicenter, open-label, two-arm, randomized, controlled study designed to evaluate the efficacy and safety of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen. The anticipated time on study treatment is based on continued clinical benefit, i.e., until disease progression or unacceptable toxicity. The target sample size is 931 participants. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody '''Start Date''': 2015-01-13 '''Last Updated''': 2019-08-01 '''Number of Patients''': 931 '''Recruitment Status''': COMPLETED '''Condition''': Bladder Cancer '''NCTID''': NCT01767155 '''Title''': [[hasTrialTitle::Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer]] '''Study Summary''': Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin. '''Sponsor''': AEterna Zentaris '''Intervention''': AEZS-108 / zoptarelin doxorubicin '''Start Date''': 2013-04 '''Last Updated''': 2018-07-31 '''Number of Patients''': 511 '''Recruitment Status''': COMPLETED '''Condition''': Endometrial Cancer '''NCTID''': NCT04221035 '''Title''': [[hasTrialTitle::High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)]] '''Study Summary''': This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma. '''Sponsor''': Gustave Roussy, Cancer Campus, Grand Paris '''Intervention''': Vincristine '''Start Date''': 2019-11-05 '''Last Updated''': 2023-02-13 '''Number of Patients''': 800 '''Recruitment Status''': RECRUITING '''Condition''': High-Risk Neuroblastoma '''NCTID''': NCT05239728 '''Title''': [[hasTrialTitle::A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)]] '''Study Summary''': The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS). '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Belzutifan '''Start Date''': 2022-03-15 '''Last Updated''': 2023-11-18 '''Number of Patients''': 1800 '''Recruitment Status''': RECRUITING '''Condition''': Carcinoma, Renal Cell '''NCTID''': NCT05020236 '''Title''': [[hasTrialTitle::MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma]] '''Study Summary''': The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide, and dexamethasone. Part 3 of the study will evaluate an alternative dosing schedule of elranatamab in combination with daratumumab. Participants in all parts of the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study. '''Sponsor''': Pfizer '''Intervention''': Elranatamab '''Start Date''': 2021-10-04 '''Last Updated''': 2023-08-24 '''Number of Patients''': 854 '''Recruitment Status''': RECRUITING '''Condition''': Multiple Myeloma '''NCTID''': NCT03059823 '''Title''': [[hasTrialTitle::A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors]] '''Study Summary''': The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules of administration among patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012 will also be assessed. The purpose of Amendment 5 is to obtain additional safety experience at the newly defined recommended Phase 2 dose of 500 mg every 4 weeks in patients with endometrial cancer, specifically either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Additionally, every 3 week (Q3W) flat-dosing will be studied in an additional tumor agnostic cohort. '''Sponsor''': Incyte Corporation '''Intervention''': retifanlimab '''Start Date''': 2016-11-15 '''Last Updated''': 2023-07-12 '''Number of Patients''': 325 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Locally Advanced Solid Tumors '''NCTID''': NCT01317641 '''Title''': [[hasTrialTitle::Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer]] '''Study Summary''': The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer. '''Sponsor''': Orion Corporation, Orion Pharma '''Intervention''': ODM-201 '''Start Date''': 2011-03 '''Last Updated''': 2017-03-29 '''Number of Patients''': 136 '''Recruitment Status''': COMPLETED '''Condition''': Prostate Cancer '''NCTID''': NCT00002840 '''Title''': [[hasTrialTitle::Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma]] '''Study Summary''': RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells, and may be an effective treatment for anaplastic oligodendroglioma. Combining combination chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare radiation therapy with and without combination chemotherapy in patients with resected anaplastic oligodendroglioma. '''Sponsor''': European Organisation for Research and Treatment of Cancer - EORTC '''Intervention''': lomustine '''Start Date''': 1996-08 '''Last Updated''': 2012-07-10 '''Number of Patients''': 350 '''Recruitment Status''': COMPLETED '''Condition''': Brain and Central Nervous System Tumors '''NCTID''': NCT02993523 '''Title''': [[hasTrialTitle::A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy]] '''Study Summary''': Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed. Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own. This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are \>= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for standard induction therapy (usual starting treatment). AbbVie is funding this study which will take place at approximately 180 hospitals globally and enroll approximately 400 participants. In this study, 2/3 of participants will receive venetoclax every day with azacitidine and the remaining 1/3 will receive placebo (dummy) tablets with azacitidine. Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires. Blood and bone marrow tests will be completed to see why some people respond better than others. Additional blood tests will be completed for genetic factors and to see how long the drug remains in the body. '''Sponsor''': AbbVie '''Intervention''': Azacitidine '''Start Date''': 2017-02-02 '''Last Updated''': 2023-07-03 '''Number of Patients''': 443 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Acute Myeloid Leukemia (AML) '''NCTID''': NCT01429064 '''Title''': [[hasTrialTitle::Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001]] '''Study Summary''': The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer. '''Sponsor''': Orion Corporation, Orion Pharma '''Intervention''': ODM-201 '''Start Date''': 2011-06 '''Last Updated''': 2017-02-20 '''Number of Patients''': 76 '''Recruitment Status''': COMPLETED '''Condition''': Prostate Cancer '''NCTID''': NCT05224141 '''Title''': [[hasTrialTitle::Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)]] '''Study Summary''': This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab/Vibostolimab Co-Formulation '''Start Date''': 2022-03-24 '''Last Updated''': 2023-10-10 '''Number of Patients''': 450 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Small Cell Lung Carcinoma '''NCTID''': NCT03293173 '''Title''': [[hasTrialTitle::Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis]] '''Study Summary''': This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL). '''Sponsor''': Nordic Lymphoma Group '''Intervention''': R-CHOEP '''Start Date''': 2017-08-04 '''Last Updated''': 2020-03-04 '''Number of Patients''': 120 '''Recruitment Status''': RECRUITING '''Condition''': Lymphoma, Large B-Cell, Diffuse '''NCTID''': NCT04634877 '''Title''': [[hasTrialTitle::Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)]] '''Study Summary''': The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS. '''Sponsor''': Merck Sharp & Dohme LLC '''Intervention''': Pembrolizumab '''Start Date''': 2021-01-10 '''Last Updated''': 2023-11-21 '''Number of Patients''': 990 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': Endometrial Neoplasms '''NCTID''': NCT05027477 '''Title''': [[hasTrialTitle::A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer]] '''Study Summary''': Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy. '''Sponsor''': Profound Medical Inc. '''Intervention''': Radical Prostatectomy '''Start Date''': 2021-11-01 '''Last Updated''': 2023-11-14 '''Number of Patients''': 201 '''Recruitment Status''': RECRUITING '''Condition''': Prostate Cancer '''NCTID''': NCT04303780 '''Title''': [[hasTrialTitle::Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200)]]. '''Study Summary''': A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation '''Sponsor''': Amgen '''Intervention''': AMG 510 '''Start Date''': 2020-06-04 '''Last Updated''': 2023-10-23 '''Number of Patients''': 345 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': KRAS p, G12c Mutated /Advanced Metastatic NSCLC '''NCTID''': NCT04764188 '''Title''': [[hasTrialTitle::An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib]] '''Study Summary''': This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice. '''Sponsor''': Hoffmann-La Roche '''Intervention''': Alectinib '''Start Date''': 2021-05-10 '''Last Updated''': 2023-11-08 '''Number of Patients''': 800 '''Recruitment Status''': ACTIVE_NOT_RECRUITING '''Condition''': NSCLC '''NCTID''': NCT02477644 '''Title''': [[hasTrialTitle::Platine, Avastin and OLAparib in 1st Line]] '''Study Summary''': Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance. '''Sponsor''': Arcagy Research '''Intervention''': Olaparib '''Start Date''': 2015-05-06 '''Last Updated''': 2022-08-02 '''Number of Patients''': 806 '''Recruitment Status''': COMPLETED '''Condition''': Ovarian Cancer '''NCTID''': NCT04307576 '''Title''': [[hasTrialTitle::A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia]] '''Study Summary''': ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design. '''Sponsor''': Mats Heyman '''Intervention''': Omitted Doxorubicin '''Start Date''': 2020-07-13 '''Last Updated''': 2023-11-21 '''Number of Patients''': 6430 '''Recruitment Status''': RECRUITING '''Condition''': Leukemia, Acute Lymphoblastic <span style="display:none">hasTrialTitle::Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)</span> <span style="display:none">hasTrialTitle::A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer</span> <span style="display:none">hasTrialTitle::Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)</span> <span style="display:none">hasTrialTitle::A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection</span> <span style="display:none">hasTrialTitle::Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer</span> <span style="display:none">hasTrialTitle::Temozolomide in Treating Patients With Recurrent Oligodendroglial Tumors</span> <span style="display:none">hasTrialTitle::A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma</span> <span style="display:none">hasTrialTitle::A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy</span> <span style="display:none">hasTrialTitle::Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count</span> <span style="display:none">hasTrialTitle::High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma</span> <span style="display:none">hasTrialTitle::Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer</span> <span style="display:none">hasTrialTitle::Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas</span> <span style="display:none">hasTrialTitle::Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia</span> <span style="display:none">hasTrialTitle::Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)</span> <span style="display:none">hasTrialTitle::Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer</span> <span style="display:none">hasTrialTitle::Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC</span> <span style="display:none">hasTrialTitle::Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC</span> <span style="display:none">hasTrialTitle::A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer</span> <span style="display:none">hasTrialTitle::A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer</span> <span style="display:none">hasTrialTitle::Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant</span> <span style="display:none">hasTrialTitle::Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study</span> <span style="display:none">hasTrialTitle::Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia</span> <span style="display:none">hasTrialTitle::The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs</span> <span style="display:none">hasTrialTitle::Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)</span> <span style="display:none">hasTrialTitle::Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)</span> <span style="display:none">hasTrialTitle::Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)</span> <span style="display:none">hasTrialTitle::A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211</span> <span style="display:none">hasTrialTitle::Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer</span> <span style="display:none">hasTrialTitle::High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)</span> <span style="display:none">hasTrialTitle::A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)</span> <span style="display:none">hasTrialTitle::MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma</span> <span style="display:none">hasTrialTitle::A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors</span> <span style="display:none">hasTrialTitle::Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer</span> <span style="display:none">hasTrialTitle::Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma</span> <span style="display:none">hasTrialTitle::A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy</span> <span style="display:none">hasTrialTitle::Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001</span> <span style="display:none">hasTrialTitle::Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)</span> <span style="display:none">hasTrialTitle::Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis</span> <span style="display:none">hasTrialTitle::Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)</span> <span style="display:none">hasTrialTitle::A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer</span> <span style="display:none">hasTrialTitle::Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200)</span> <span style="display:none">hasTrialTitle::An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib</span> <span style="display:none">hasTrialTitle::Platine, Avastin and OLAparib in 1st Line</span> <span style="display:none">hasTrialTitle::A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia</span> <span style="display:none">hasCancerType::C00-D48: All neoplasms</span> <span style="display:none">hasCancerType::C00-C97: All cancer types</span> <span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span> <span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span> <span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span> <span style="display:none">hasCancerType::C40-C41: Bone cancers</span> <span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span> <span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span> <span style="display:none">hasCancerType::C50: Breast cancer</span> <span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span> <span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span> <span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span> <span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span> <span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span> <span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span> <span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span> <span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span> <span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span> <span style="display:none">hasCancerType::D10-D36: Benign tumour</span> <span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span> <span style="display:none">hasCancerType::unknown</span> <span style="display:none">isTrial</span>
Summary:
Please note that all contributions to Beacon may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Beacon:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Tools
What links here
Related changes
Special pages
Page information
